Description: Cannabics Pharmaceuticals Inc., formerly American Mining Company, is a biotechnology pharmaceutical company. The Company is engaged in pharmaceutical development. The Company is focused on development and licensing of cannabinoid-based treatments and therapies. It develops and markets various therapies and biotechnological tools aimed at providing relief from ailments that respond to active ingredients sourced from the cannabis plant. These tools include delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds, and bioinformatics tools. The Company's flagship product is CANNABICS SR. CANNABICS SR is a technology for a long acting oil capsule that provides administration of cannabis. CANNABICS SR is composed solely from food grade materials and delivers effects for over 10 to 12 hours. The delivery method enables a once per day dosing regimen of medical cannabis to patients. It has not generated revenues.
Home Page: www.cnbxpharma.com
#3 Bethesda Metro Center
Bethesda,
MD
20814
United States
Phone:
877 424 2429
Officers
| Name | Title |
|---|---|
| Mr. Gabriel Yariv | Pres, COO & Exec. Chairman |
| Mr. Eyal Barad | Co-Founder, CEO & Director |
| Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Dr. Sanja Goldberg | Chief Technology Officer |
| Noam Permont | VP of PR & Investor Relations |
| Dr. Sigalit Ariely-Portnoy Ph.D. | Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board |
| Dr. Tal Mofkadi Ph.D. | Financial Advisor & Member of Advisory Board |
| Mr. Yasha Borstein | Chief Data Officer |
| Dr. Yaakov Waksman | Head of Cannabidiol Research |
| Dr. Ilya Reznik M.D. | Head of Neuropsychiatry Devel. |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 20.3879 |
| Price-to-Sales TTM: | 7565.9814 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 5 |